竞争性酸阻塞剂:当前的临床使用和未来的发展
Carmelo Scarpignato1,2,3,4, Richard H Hunt5
1Department of Medicine & Surgery, University of Parma, Parma, Italy. carmelo.scarpignato@unipr.it.
Current gastroenterology reports
|August 15, 2024
概括
新的竞争性酸阻塞剂 (P-CABs) 改善了对诸如GERD和H. pylori感染等疾病的酸抑制,解决了传统质子抑制剂 (PPI) 的局限性. 对这些新型抗分泌药物需要进一步的长期安全数据.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 质子抑制剂 (PPI) 是酸性相关疾病的标准,但有局限性.
- 在管理GERD,H. pylori和NSAID相关的方面,仍然存在未满足的临床需求.
- 限制包括不一致的酸性抑制和夜间酸度控制不良.
研究的目的:
- 审查竞争性酸阻断剂 (P-CABs) 的现状和未来发展.
- 突出P-CABs作为一种新的抗分泌药物类别.
- 为了将P-CAB与现有的抑制酸的药物进行比较.
主要方法:
- 对P-CAB和PPI的文献综述.
- 对P-CABs在GERD和H. pylori根除中的临床试验数据的分析.
- 疗效和安全性概况的比较.
主要成果:
- P-CABs (vonoprazan,tegoprazan,fexuprazan,keverprazan) 解决了在酸性抑制方面尚未满足的需求.
- 在GERD和H. pylori根除方面,P-CABs表现出与PPI相似或更高的疗效.
- P-CABs的短期安全性与PPI相当;长期数据正在等待.
结论:
- 在酸抑制治疗中,P-CABs代表了一个有前途的进步.
- 这些新型药物为管理复杂的酸性疾病提供了潜在的解决方案.
- 进一步的长期研究是必不可少的,以充分确定P-CABs的安全性.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
482
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
482
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
940
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
940
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
361
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
361
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
552
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
552


